An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris

Main Article Content

Linda Stein Gold
Sunhil Dhawan
Jonathan Weiss
Zoe Diana Draelos
Herman Ellman
Iain Stuart

Keywords

acne, minocycline

Abstract

Abstract not available.

References

1. Biswal I, Gaind R, Kumar N, et al. In vitro antimicrobial susceptibility patterns of Propionibacterium acnes isolated from patients with acne vulgaris. J Infect Dev Ctries. 2016;10(10):1140-1145.

2. Gold LS, Dhawan S, Weiss J, et al. A novel topical minocycline foam for the treatment of moderateto-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019;80(1):168-177.

3. Raoof J, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: a phase 3 study. J Am Acad Dermatol. 2019; Jun 1 [Epub ahead of print].